Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xyrem in Pediatric Narcolepsy with Cataplexy
NCT02221869Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Narcolepsy type 1 (NT1) comparing Xyrem with Placebo (2 arms). Primary endpoint: Change in Weekly Number of Cataplexy Attacks at 2 weeks. Started Oct 2014; status: completed.
02
Drugs
sodium oxybate
03
Conditions
Narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT02221869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221869.